Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PREP | P48147 | 2/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.46 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28943687 | 1.00 | PREP (0.51) | PREPALDH1A1OPRK1GAA | |
| SCHEMBL1189714 | 0.97 | PREP (0.50) | PREPALDH1A1OPRK1GAA | |
| SCHEMBL17293555 | 0.91 | PREP (0.49) | PREPALDH1A1OPRK1 | |
| SCHEMBL1816147 | 0.91 | PREP (0.49) | PREPALDH1A1OPRK1 | |
| SCHEMBL24555463 | 0.89 | PREP (0.48) | PREPALDH1A1OPRK1 | |
| SCHEMBL22811016 | 0.86 | PREP (0.45) | PREPALDH1A1OPRK1 | |
| SCHEMBL2084087 | 0.84 | PREP (0.49) | PREP | |
| SCHEMBL2084231 | 0.84 | PREP (0.48) | PREPALDH1A1OPRK1 | |
| SCHEMBL22964984 | 0.82 | FOLH1 (0.51) | PREP | |
| SCHEMBL22965036 | 0.82 | ITGB3 (0.43) | PREPALDH1A1OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11370755-B2 | Compositions of trofinetide | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2022-06-28 | — | — | US | disclosed |
| CN-114667136-A | Composition of TROFINETIDE | 诺仁制药有限公司 | 2022-06-24 | — | — | CN | disclosed |
| WO-2021026066-A1 | COMPOSITIONS OF TROFINETIDE | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2021-02-11 | — | — | WO | disclosed |
| EP-2667715-B1 | TREATMENT OF AUTISM SPECTRUM DISORDERS USING GLYCYL-L-2-METHYLPROLYL-L-GLUTAMIC ACID | NEUREN PHARMACEUTICALS LTD (NZ) | 2017-07-19 | — | — | EP | disclosed |
| EP-2667715-B1 | TREATMENT OF AUTISM SPECTRUM DISORDERS USING GLYCYL-L-2-METHYLPROLYL-L-GLUTAMIC ACID | NEUREN PHARMACEUTICALS LTD (NZ) | 2017-07-19 | — | — | EP | disclosed |
| US-9708366-B2 | Treatment of fragile X syndrome using glycyl-L-2-methylprolyl-L-glutamate | NEUREN PHARMACEUTICALS LTD. (NZ) | 2017-07-18 | — | — | US | disclosed |
| US-9708366-B2 | Treatment of fragile X syndrome using glycyl-L-2-methylprolyl-L-glutamate | NEUREN PHARMACEUTICALS LTD. (NZ) | 2017-07-18 | — | — | US | disclosed |
| US-9212204-B2 | Treatment of rett syndrome using glycyl-L-2-methylprolyl-L-glutamic acid | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2015-12-15 | — | — | US | disclosed |
| US-9212204-B2 | Treatment of rett syndrome using glycyl-L-2-methylprolyl-L-glutamic acid | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2015-12-15 | — | — | US | disclosed |
| EP-2928300-A1 | TREATMENT OF AUTISM SPECTRUM DISORDERS USING GLYCYL-L-2-METHYLPROLYL-L-GLUTAMIC ACID | Neuren Pharmaceuticals Limited (NZ) | 2015-10-14 | — | — | EP | disclosed |
| US-7605177-B2 | Effects of glycyl-2 methyl prolyl glutamate on neurodegeneration | NEUREN PHARMACEUTICALS LIMITED (NL) | 2009-10-20 | — | — | US | disclosed |
| US-20080145335-A1 | Analogs of Glycyl-Prolyl-Glutamate | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2008-06-19 | — | — | US | disclosed |
| US-20070298009-A1 | Effects of glycyl-2 methyl prolyl glutamate on neurodegeneration | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2007-12-27 | — | — | US | disclosed |
| US-20070298009-A1 | Effects of glycyl-2 methyl prolyl glutamate on neurodegeneration | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2007-12-27 | — | — | US | disclosed |
| US-20070298009-A1 | Effects of glycyl-2 methyl prolyl glutamate on neurodegeneration | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2007-12-27 | — | — | US | disclosed |
| US-20070004641-A1 | Cognitive enhancement and cognitive therapy using glycyl-L-2-methylprolyl-L-glutamate | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2007-01-04 | — | — | US | disclosed |
| US-20070004641-A1 | Cognitive enhancement and cognitive therapy using glycyl-L-2-methylprolyl-L-glutamate | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2007-01-04 | — | — | US | disclosed |
| US-20070004641-A1 | Cognitive enhancement and cognitive therapy using glycyl-L-2-methylprolyl-L-glutamate | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2007-01-04 | — | — | US | disclosed |
| US-20060251649-A1 | Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2006-11-09 | — | — | US | disclosed |
| US-20060251649-A1 | Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate | NEUREN PHARMACEUTICALS LIMITED (NZ) | 2006-11-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070298009-A1 | Effects of glycyl-2 methyl prolyl glutamate on neurodegeneration | GRM2, GRM1, GLUL | PREP 48/4885ALDH1A1 4078/4885OPRK1 2055/4885 |
| US-20080145335-A1 | Analogs of Glycyl-Prolyl-Glutamate | GLS, GLUL, HIF1A | PREP 24/4885ALDH1A1 574/4885OPRK1 732/4885 |
| US-20060251649-A1 | Treatment of non-convulsive seizures in brain injury using G-2-methyl-prolyl glutamate | GRM2, GRIN2C, GRIN2A | PREP 90/4885ALDH1A1 2555/4885OPRK1 2179/4885 |
| US-20070004641-A1 | Cognitive enhancement and cognitive therapy using glycyl-L-2-methylprolyl-L-glutamate | CHAT, GAP43, BCHE | PREP 109/4885ALDH1A1 2612/4885OPRK1 2645/4885 |
| US-11370755-B2 | Compositions of trofinetide | TXNRD2, BDNF, TTPA | PREP 2629/4885ALDH1A1 113/4885OPRK1 1897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.